Celecoxib (Celebrex) Evidence‑Based Recommendations

Cardiovascular Risk Mitigation

Use the lowest effective dose for the shortest duration needed to minimize cardiovascular events, as recommended by cardiovascular safety guidelines. 1

Celecoxib has a lower rate of complicated gastrointestinal ulcers (≈0.8%) than non‑selective NSAIDs, indicating superior GI safety in patients without additional risk factors. 2
Concomitant low‑dose aspirin (≤325 mg/day) substantially reduces celecoxib’s GI advantage, eliminating most of the ulcer‑protective benefit. 2
When aspirin is co‑prescribed, the rate of complicated ulcers rises four‑fold (≈1.1% vs 0.3% with celecoxib alone). 2
Patients with a history of peptic ulcer disease experience markedly higher ulcer rates (≈2.6% with celecoxib alone and ≈6.9% when combined with aspirin). 2

Patients with prior ulcer complications should receive gastro‑protective therapy even when treated with celecoxib. 4
Avoid concurrent use of celecoxib with other NSAIDs, systemic corticosteroids, or anticoagulants whenever possible to reduce additive GI and bleeding risk. 4
A comprehensive risk‑assessment step (including prior GI events, cardiovascular disease, renal function, aspirin use, age ≥ 65 years, hepatic function, and CYP2C9 status) is recommended before initiating celecoxib therapy. 4